*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**Mega Genomics Limited**
**美因基因有限公司***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 6667)**

# SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2026

Reference is made to the interim results announcement of Mega Genomics Limited (the "**Company**", together with its subsidiaries, the "**Group**") dated 31 August 2026 for the six months ended 30 June 2026 (the "**2026 Interim Results Announcement**") and the interim report of the Company for the same period published on 30 September 2026 (the "**Interim Report**"). Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the 2026 Interim Results Announcement.

The board of directors of the Company (the "**Board**") wishes to provide the following additional information to the shareholders of the Company (the "**Shareholders**") and potential investors in relation to the Group's management discussion and analysis.

## ANCILLARY SERVICES AND RELATED PRODUCTS

### Nature of the business and product offerings

The Group's business comprises the provision of testing services and the sale of ancillary testing materials and related products. In the 2026 Interim Results Announcement, the testing services were classified as consumer genetic testing services and cancer screening services, and sales of ancillary testing materials were classified as ancillary services and related products.

The ancillary services and related products business involves the sale of materials and ancillary consumables used for medical testing (the "**Testing Materials**"), such as blood collection tubes and folate testing reagents, to health check-up centres, hospitals and other healthcare institutions.

**Sources of customers and suppliers**

The Group has developed its customers primarily by leveraging the healthcare channel resources accumulated over many years. It has established cooperation with health check-up centres, hospitals and other healthcare institutions in more than 340 cities in China, providing a broad and stable healthcare network for the development of its business.

The Group's principal suppliers of Testing Materials comprise leading PRC enterprises in the in vitro diagnostics industry, most of which are companies listed in the PRC or overseas.

**Development of the business and financial performance**

The Group offers a broad range of testing items. Building on its more competitive service quality, the Group supplies customers with Testing Materials ancillary to its testing services as well as those required for customers to conduct testing in-house. It provides customers with integrated laboratory testing solutions comprising testing services and sales of ancillary Testing Materials, thereby driving growth in the related sales revenue. Customers may purchase certain Testing Materials without concurrently procuring testing services from the Group. Customers may conduct the relevant testing in-house or outsource it to other testing institutions or the Group.

In previous years, the Group also charged for Testing Materials supplied in conjunction with its testing services, with the related sales being relatively small in scale.

Revenue from ancillary services and related products amounted to approximately RMB114.2 million for the year ended 31 December 2025, mainly in the second half of that year. For the six months ended 30 June 2026 (the "**Reporting Period**"), revenue from ancillary services and related products amounted to approximately RMB109.8 million, and the gross profit margin from the sale of Testing Materials was 28.6%, with the Group recording the same gross profit margins on sales of comparable products or provision of comparable services to connected persons and independent third parties. The business has operated steadily following its expansion in the second half of 2025.

By pooling procurement demand from independent third-party customers and Meinian OneHealth and its associates, the Group achieves larger purchase volumes and greater economies of scale than individual customers purchasing on their own, enabling it to obtain more competitive prices from upstream suppliers.

The Group also integrates resources across multiple categories of Testing Materials to provide customers with one-stop procurement services, reducing the burden of dealing with multiple upstream suppliers. It coordinates logistics scheduling and the handling of product issues, and provides services including batch traceability and expiry-date management. Centralised procurement improves efficiency and reduces costs in logistics, human resources and warehousing, creating a win-win situation for the Group and all its customers.

The Group stocks goods in advance to support continuous and stable supply, and bears risks and costs relating to inventory, tied-up capital, logistics and transportation. While providing the above services and bearing the associated risks and costs, the Group can thereby expand the scale of its sales and earn returns.

The Group intends to broaden its range of testing items and product categories and provide customers with integrated services comprising both testing services and Testing Materials. It will also determine the future scale of ancillary services and related products flexibly by reference to actual customer demand. Supported by its high-quality and convenient value-added services and its high-volume, low-margin sales model, the Group expects this business to develop steadily in the future.

## GENETIC KITS BUSINESS AND THIRD-PARTY PROMOTERS

Reference is made to the resumption announcement of the Company dated 26 February 2026. The Board wishes to provide the following updates to the Shareholders and potential investors in relation to the Group's genetic testing kits business and use of third-party promoters.

### Genetic Kits business

Since the third quarter of 2025, the Group has gradually shifted the focus of its marketing efforts back to the on-site sample collection and testing business. The genetic testing kits (the "**Genetic Kits**", each a "**Genetic Kit**") business is no longer a key area of promotion. The Group continues to perform its contractual obligations to provide testing services and deliver reports for outstanding orders for which payment was received in previous months. Where a customer places an order for a Genetic Kit product on its own initiative, the Group continues to provide services in accordance with its prevailing standards. The Group expects the order volume and the proportion of revenue contributed by the Genetic Kits business to decrease gradually.

The Group's revenue from consumer genetic testing services for the six months ended 30 June 2026 and 2025 is broken down as follows. Percentages represent the proportion of revenue from consumer genetic testing services.

| | **2026** | **2026** | **2025** | **2025** |
|---|---|---|---|---|
| | *RMB'000* | *%* | *RMB'000* | *%* |
| Genetic Kits business | 16,432 | 21.4 | 46,371 | 61.1 |
| Direct testing services | 60,400 | 78.6 | 29,501 | 38.9 |
| **Total** | **76,832** | **100.0** | **75,872** | **100.0** |

Revenue from the Genetic Kits business accounted for 61.1% of revenue from consumer genetic testing services for the six months ended 30 June 2025 and 21.4% for the Reporting Period, a year-on-year decrease of 39.7 percentage points. The decrease in the proportion of revenue from the Genetic Kits business is consistent with the Group's shift in the focus of its marketing efforts back to the on-site sample collection and testing business since the third quarter of 2025.

**Third-party promoters**

The Company has not renewed cooperation agreements with Genetic Kit promoters whose agreements have expired. For those agreements which have not yet expired, the Company will not enter into new cooperation agreements with the relevant promoters upon expiry.

The Company's promotional activities are currently carried out jointly by its internal team and third-party promoters whose agreements have not yet expired. Upon expiry of all such agreements, the promotional activities will be undertaken entirely by the Company's internal team.

This announcement should be read in conjunction with the 2026 Interim Results Announcement and the Interim Report.

By order of the Board
**Mega Genomics Limited**
**Ms. LIN Lin**
*Executive Director and Chairperson*

Hong Kong, 11 November 2026

*As at the date of this announcement, the executive Directors of the Company are Dr. Yu Rong, Ms. Lin Lin and Ms. Jiang Jing; the non-executive Director of the Company is Ms. Guo Meiling; and the independent non-executive Directors of the Company are Dr. Zhang Ying, Mr. Jia Qingfeng and Dr. Xie Dan.*

* *For identification purpose only*